Savarese Gianluigi, Becher Peter Moritz, Lund Lars H, Seferovic Petar, Rosano Giuseppe M C, Coats Andrew J S
Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by significant morbidity and mortality, poor functional capacity and quality of life, and high costs. HF affects more than 64 million people worldwide. Therefore, attempts to decrease its social and economic burden have become a major global public health priority. While the incidence of HF has stabilized and seems to be declining in industrialized countries, the prevalence is increasing due to the ageing of the population, improved treatment of and survival with ischaemic heart disease, and the availability of effective evidence-based therapies prolonging life in patients with HF. There are geographical variations in HF epidemiology. There is substantial lack of data from developing countries, where HF exhibits different features compared with that observed in the Western world. In this review, we provide a contemporary overview on the global burden of HF, providing updated estimates on prevalence, incidence, outcomes, and costs worldwide.
心力衰竭(HF)是一种多方面且危及生命的综合征,其特征为高发病率和死亡率、功能能力及生活质量差以及成本高昂。全球有超过6400万人受HF影响。因此,减轻其社会和经济负担的努力已成为全球主要的公共卫生优先事项。虽然在工业化国家HF的发病率已趋于稳定且似乎在下降,但由于人口老龄化、缺血性心脏病治疗和生存率的提高以及有效循证疗法的出现延长了HF患者的寿命,其患病率正在上升。HF的流行病学存在地域差异。发展中国家的数据严重不足,在这些国家,HF表现出与西方世界不同的特征。在本综述中,我们提供了关于HF全球负担的当代概述,给出了全球患病率、发病率、结局和成本的最新估计。